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1. Introduction 
Effective control of pathogens is typically achieved by the timely interplay between the 
innate and adaptive immune response of an individual. The first-line of defence of the host 
immune system is our skin and mucosal membranes, which form a physical and chemical 
barrier. If a pathogen gains access to the body, for example when there is skin damage, cells 
of our innate immune system recognise pathogens by means of receptors (acting as 
sentinels) binding common motifs on pathogen surfaces and mount an immediate non-
specific effector response. Often this response leads to the destruction of the pathogens, but 
also the production of secreted proteins such as interferons (IFNs) or cytokines, which help 
the interaction between the various cells involved in the immune response. This initial 
“inflammation” of the infected tissue commonly leads to the recruitment of lymphocytes to 
the site and triggers a more pathogen-specific response known as the adaptive immune 
response. In addition, local inflammation triggers activation of the complement system, a 
group of plasma proteins, which can recruit further immune cells to the site or be directly 
proteolytic to bacterial surfaces (Janeway 2008).  
Not surprisingly, there are multiple genes that code for the molecules of the innate and 
adaptive host immune response. Between individuals, these genes can show variations 
within the coding sequence itself and/or within associated regulatory elements such as 
promoters. Furthermore, many of these genes are part of multicopy gene families resulting 
from previous gene duplication events (Kelley and Trowsdale 2005). Gene duplication can 
lead to new gene copies developing complementary and/or overlapping functions allowing 
for redundancy in the immune system and the ability to cope with a number of different 
pathogens (Nei, Gu et al. 1997).  
Some of the genetic characteristics of the immune system predate mammalian divergence 
while others reflect more recent primate and human evolution. However, all living species, 
including humans, have been under constant bombardment from pathogens over thousands 
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or millions of generations and it is likely that this host/pathogen interaction has to a large 
extent shaped the genetics of both host and pathogen populations.  
Remarkably, for some highly mutable and therefore rapidly changing pathogens such as 
HIV and the Hepatitis C virus (HCV), two small RNA viruses, viral adaptation to the host’s 
immune response results in characteristic variations in the virus that allow the virus to 
effectively escape a particular immune response. In contrast, larger, complex DNA viruses, 
such as Herpes viruses, with a more rigid genome have the coding capacity for additional 
genes, which interfere specifically with the immune response of the host (Lucas, Karrer et al. 
2001). The multitude of escape strategies presented to our immune system, highlights the 
diversity of modifications needed to successfully combat the pathogens of our modern 
times. Furthermore, the result of these selective forces on the host over thousands of 
generations is the extensive host genetic diversity of immune response genes we observe 
today in all populations.  
2. Examples of genetic diversity of the immune response genes 
Two genetic systems that are commonly associated with variable infection outcomes are the 
killer-immunoglobulin like receptors (KIRs) present on NK cells that can determine the 
activatory or inhibitory propensity of the NK cell as part of the innate immune response and 
human leucocyte antigens (HLA) that present processed antigens to T lymphocytes, which 
are part of the adaptive immune response. These two genetic systems are also functionally 
connected; HLA molecules are ligands for the KIRs and their particular combinations add 
another layer of complexity to the differential immune response exhibited by individuals to 
particular pathogens. 
2.1 KIR genetic diversity 
The region of chromosome 19q13.4 containing the KIR genes is characterised by 
polymorphism, gene duplication, and linkage disequilibrium leading to KIR haplotypes 
spanning several hundred kilobases (Martin, Kulski et al. 2004). Genetic variation between 
haplotypes presents as allelic variation at specific loci and variation in gene content (Martin, 
Kulski et al. 2004; Pyo, Guethlein et al. 2010).  
The KIRs can be separated into KIR2D and KIR3D genes based on the number of 
extracellular immunoglobulin domains. Further differentiation occurs based on the length of 
their cytoplasmic domain (short – S and long – L). Those KIR genes with a short cytoplasmic 
tail that lack an ITIM motif confer an activatory phenotype to the KIR2D and 3D genes while 
longer cytoplasmic domains with an ITIM motif confers an inhibitory phenotype. 
Sequencing of the KIR region and of individual genes shows extensive allelic diversity for 
both activatory and inhibitory genes (Table 1). 
The effects of KIRs on host immune responses are mediated by specific cognate interactions 
between these receptors and their natural HLA Class I ligands on the surface of target cells, 
which may result in either activation or inhibition of NK cell cytotoxicity (Lanier 1998). The 
presence of particular HLA-B/-C alleles will determine the repertoire of inhibitory and 
activatory ligands that can be utilised by KIRs to modulate NK cell mediated responses. 
Several KIR and HLA combinations have been associated with both infectious disease 
outcome (Khakoo, Thio et al. 2004) and autoimmune diseases (Martin, Nelson et al. 2002). A 
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functional model for the interaction between KIR and their HLA ligands has been proposed 
to account for a suspected hierarchy of inhibitory NK cell responses that may reflect the 
disease associations (Kulkarni, Martin et al. 2008). In this model, individuals with KIR 
haplotypes carrying a greater number of activatory genes, and with the appropriate HLA 
Class I ligands, may exhibit lower inhibition and higher activation (activatory phenotype), 
which may be beneficial in viral infections but may also correlate to a greater risk of 
developing autoimmunity.  
2.2 HLA genetic diversity 
The HLA genetic system within the Major Histocompatibility Complex (MHC) on the short 
arm of chromosome 6 is the most polymorphic in humans. Similar to the KIR region, the 
MHC region is characterised by extensive intra- and inter-genic polymorphism (Gaudieri, 
Dawkins et al. 2000), segment duplications (containing more than a single gene or gene 
fragment) (Gaudieri, Kulski et al. 1999) and linkage disequilibrium leading to haplotypes 
containing HLA and other immune-related genes that stretch hundreds of kilobases and 
even megabases. One major difference between KIR and MHC haplotypes is that within the 
MHC, for the most part, all individuals have the same number of HLA Class I and II genes 
but heterozygosity values at each locus is high.  
The HLA family comprises class I and class II molecules that can present processed antigen 
to CD8+ and CD4+ T lymphocytes, respectively. The HLA Class I molecules including HLA-
A, -B and –C are expressed on all nucleated cells and share significant similarity reflecting 
largely overlapping functions but with some important distinctions, including their function 
as NK cell receptor ligands. The HLA Class II molecules including HLA-DR, -DQ and –DP 
are expressed on antigen-presenting cells. Orthologues of the HLA Class I and II genes are 
present in other primates and most vertebrates. 
HLA molecules were initially identified via their involvement in self-nonself discrimination 
in transplantation. Serology-based assays using anti-HLA antibodies were used to match 
donor and recipient pairs prior to transplantation. These initial HLA typing assays were 
able to differentiate dozens of HLA Class I and II proteins (Graw, Goldstein et al. 1970). 
However, it was not until sequence-based typing was developed in the 1990s that the extent 
of genetic variation within these genes became apparent.  Several hundred to thousands of 
alleles have now been described for many of the HLA Class I and II loci (Table 1).  
Much of the variation within HLA genes exists in the peptide binding domains of the 
molecule. Individuals with different HLA types can therefore present different parts of the 
pathogen to T lymphocytes and it is thought that the variation observed within the HLA 
peptide binding domains are driven by positive selection pressures that favour the 
maintenance of polymorphism in this system (Hughes, Ota et al. 1990). Support for this is 
provided by several studies that show evidence for heterozygote advantage at the HLA loci 
following HIV and HCV infection (Carrington, Nelson et al. 1999; Hraber, Kuiken et al. 2007); 
with heterozygotes presenting a greater variety of peptides to T lymphocytes. Furthermore, 
studies examining pathogen-load in different human populations suggest pathogen-selection 
has been one of the driving forces in shaping the extensive variation we observe today in the 
HLA system (Prugnolle, Manica et al. 2005). However, variation outside the peptide binding 
domain can also be important as has been shown for HIV (Fellay, Shianna et al. 2007). In some 
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cases, these variations may alter the effect of microRNAs on transcribed species and ultimately 
the expression level of HLA on the cell surface (Kulkarni, Savan et al. 2011).  
 
Family Gene Alleles 
HLA Class I 
A 1,698 
B 2,271 
C 884 
HLA Class II 
DRB1 975 
DQB1 158 
DPB1 149 
MIC 
MICA 77 
MICB 33 
KIR2D 
2DL1 43 
2DL2 28 
2DL3 34 
2DL4 46 
2DL5 41 
2DS1 15 
2DS2 22 
2DS3 14 
2DS4 30 
2DS5 16 
2DP1 22 
KIR3D 
3DL1 73 
3DL2 84 
3DL3 107 
3DS1 16 
3DP1 23 
*Data from International Immunogenetics Project (www.ebi.ac.uk) release date April 2011 for KIR and 
July 2011 for MIC and HLA. 
Table 1. Number of alleles of variable host immune-related genes* 
Given the central role of HLA in the adaptive and innate immune response, it is  
not surprising that the outcome of hundreds of diseases have been associated with  
certain HLA alleles and more generally with genes within the MHC region. However, the 
intrinsic properties of the region, particularly the extensive linkage disequilibrium,  
have made the delineation of specific disease genes or alleles difficult (Dawkins, Leelayuwat 
et al. 1999).  
2.3 Diversity of other genes involved in host immune response 
Other genes within the MHC that also exhibit allelic variation include the MIC genes (MICA 
and MICB) that are ligands for the activatory NK cell receptor NKG2D. This gene family 
also has multiple gene copies in the genome with extensive diversity (Table 1). Interestingly, 
the HLA-B and -C genes and MICA (and to a lesser extent MICB) are within a region of 
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approximately 200kb in the MHC and are in strong linkage disequilibrium such that specific 
combinations of alleles for these genes are commonly inherited together. Again, this 
represents a problem when geneticists try to disentangle disease associations with these 
genes. On the other hand, the genetic proximity of these genes is likely to have functional 
consequences for NK cell and T lymphocyte function. This highlights the importance of 
assessing clusters of related genes as opposed to studying genes in isolation. In-vitro and in-
vivo studies that can better understand the immunological relevance of specific allelic 
combinations of these genes are therefore needed. 
Other immune-related genes within the MHC are positioned between the HLA Class I and 
II genes (sometimes referred to as the HLA Class III region). Genes within this region 
include the central mediating cytokine Tumour Necrosis Factor alpha gene (TNF-), which 
exhibits variations within the regulatory portion of the gene; this may lead to different 
expression and secretion levels of the cytokine. Furthermore, variations within the TNF-
gene and surrounding region also form haplotypes (Allcock, Windsor et al. 2004) 
reinforcing the need to functionally assess the relevance of combinations of variations 
within a cluster rather than a single polymorphism. 
The IFN genes involved in antiviral immune responses are also an example of a complex 
gene family including IFN-, - and -each with several subtypes and in some  
cases allelic variation. The IFN- family includes the genes IL28A, IL28B and IL29 on 
chromosome 19. Genetic variation of the IL28B gene (encoding IFN-3) has become  
of recent interest in the field of Hepatitis C due to the identification of variations 
upstream of this gene associated with HCV infection and treatment outcome in recent 
genome-wide association studies (GWAS) (discussed later). Additional variation is  
also observed for toll-like receptors (TLRs), all of which are associated with the host’s 
immune response. 
3. Hepatitis C infection: A case example demonstrating the effect of host and 
viral genetic diversity on infection outcome 
Hepatitis C is a global health issue with more than 170 million people worldwide suspected 
of carrying the virus. Variations in the global distribution of HCV reflect different exposure 
risks. In developed nations emergence of new cases is predominantly associated with the 
use of intravenous drugs while in developing nations the use of unscreened blood or blood 
products and increasing use of intravenous drugs are the leading causes of new cases 
(Shepard, Finelli et al. 2005) (Lavanchy 2011) (Dore, Law et al. 2003).  
HCV is a single-stranded RNA virus and following infection about 30% of individuals 
spontaneously clear the virus within the first six months of infection. The majority of 
individuals develop chronic infection of which about 20% develop cirrhosis and 3% develop 
hepatocellular carcinoma (Venook, Papandreou et al. 2010) (NIH 2002). In developed 
countries, HCV infection is a major indicator for liver transplantation. Current standard of 
care for HCV involves the use of pegylated-interferon alpha in combination with ribavirin 
(pegIFN-/RBV) but this treatment regime is effective in only about 50% of cases and is 
typically associated with a plethora of side-effects. There is no protective or therapeutic 
vaccine available for HCV. 
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Like other complex diseases, HCV infection and treatment outcome is the result of 
interactions between various host and viral determinants. The classical approach of 
heritability estimates using family and twin studies indicate a significant genetic 
contribution to HCV infection outcomes (Goncales, Fernando et al. 2000; Fried, Kroner et al. 
2006). In a study including 3993 haemophilia individuals infected with HCV, the 
concordance rate between 257 sibling pairs was two-fold higher than randomly paired 
subjects for spontaneous and treatment-related clearance of HCV. The heritability estimate 
from the study was approximately 0.3 (heritability of 1 indicates total phenotype variation 
due to genetic differences). These findings indicate that genetic factors play an important 
role in HCV disease outcome. This review will focus on genetic variability in host and viral 
determinants to provide an insight into the possible mechanisms underlying HCV infection 
and treatment outcome. 
3.1 Host genetic diversity and natural history of HCV infection 
Upon infection, HCV triggers the host innate and adaptive immune responses. Accordingly, 
many studies have shown that polymorphisms in genes involved in the host’s innate and 
adaptive immune response are associated with HCV infection outcome (reviewed in (Rauch, 
Gaudieri et al. 2009) (Schmidt, Thimme et al. 2011) ; Figure 1 and Table 2). Nevertheless, we 
still lack clear understanding of the underlying mechanisms by which a person develops 
chronic infection or progresses to end-stage liver disease.  
 
Fig. 1. Host genetic factors and viral adaptation associated with natural history of HCV 
infection outcome. The metabolic and fibrogenic genes are part of a seven gene signature 
used to predict liver fibrosis (Huang, Shiffman et al. 2007).        
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Gene family Gene/Allele Outcome 
HLA class I 
&II 
HLA-A*03,-A*02 , -A*11,-B*57,-B*27,-Cw*05, 
Cw*01 
Spontaneous clearance HLA –DRB1*01,-DQB1*05,-DQB1*03,-
DRB1*04, -DRB1*15,-DRB1*11, -DRB1*08 
 
HLA-A*23,-A*01, -B*53,-B*08, -B*61, -B*38, 
Cw*04, -Cw*07, Cw*03 Persistence 
HLA-DRB1*03, -DRB1*07, -DQB1*02,-
DRB1*08,-DQB1*06 
HLA-A*24,-B*40 SVR 
ISGs 
PKR -168 CT genotype 
MxA -88T  Spontaneous clearance 
OAS-1 polymorphism in 3’UTR- GG 
genotype Persistence 
MxA -88T  SVR 
OAS-1 – rs3213545 T, rs1169279 A and 
rs2859398 C alleles SVR 
SOCS3 -4874 AA genotype Treatment 
KIR KIR2DL3-HLA-C ligand  Spontaneous Clearance 
KIR2DL2/2DL3-HLA-C1C1 Treatment 
IFNs 
IL-28B - rs12979860 CC genotype 
IL-28B – rs8099917 TT genotype Spontaneous Clearance and SVR 
IFN-γ -764G 
TLR TLR-7 variants Persistence 
Cytokines 
IL-10-592AA genotype 
Spontaneous Clearance TNFα -863C/-308G haplotype (black subjects), -863C  
IL-18 –607A, -137C 
IL-10 -1082 GG genotype Persistence 
IL-10 - ACC promoter haplotype  
IL-10 -592AA,-819TT genotypes  SVR 
IL-12B – 3’UTR 1188C  
IL-18 – 607A  
IL-6 -572C 
Progression to liver fibrosis 
IL-18 -607C/*, IL-18 -137G/*, IFN-Ǆ 874T/*, 
IL-10 -1082A/A 
IL-10 -824T, -1087A, -1087/-824 haplotypes 
AT and AC 
SOCS3 = suppressor of cytokine signalling 3. Underlined HLA alleles appear in more than one study. 
References: (Thio, Gao et al. 2002; McKiernan, Hagan et al. 2004; Wang, Zheng et al. 2009), (Thio, 
Thomas et al. 2001; Yee 2004; Yoon, Han et al. 2005; Ksiaa, Ayed-Jendoubi et al. 2007; Harris, Sugimoto 
et al. 2008), (Ishida, Ikebuchi et al. 2011), (Falleti, Fabris et al. 2010), (Haas, Weiß et al. 2009), (Mueller, 
Mas-Marques et al. 2004), (Yee, Tang et al. 2001) (Morgan, Lambrecht et al. 2008), (Thio, Goedert et al. 
2004; Paladino, Fainboim et al. 2006), (Knapp, Hennig et al. 2003; Lio, Caruso et al. 2003; Kimura, Saito 
et al. 2006; An, Thio et al. 2008), (Schott, Witt et al. 2008), (Huang, Yang et al. 2007), (Ge, Fellay et al. 
2009; Mangia, Thompson et al. 2010), (Tanaka, Nishida et al. 2009; Rauch, Kutalik et al. 2010), 
(Vejbaesya, Nonnoi et al. 2011), (Khakoo, Thio et al. 2004; Montes-Cano, Caro-Oleas et al. 2005), 
(Persico, Capasso et al. 2008), (Su, Yee et al. 2008), (Suzuki, Arase et al. 2004), (Knapp, Yee et al. 2003), 
(Dai, Chuang et al. 2010). 
Table 2. Immune response gene polymorphisms associated with HCV infection and 
treatment outcome 
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3.1.1 Candidate gene studies 
3.1.1.1 Immune response genes associated with HCV outcome 
The innate immune system has a critical role in detecting pathogens and triggering the 
immune response. TLRs activate the innate immune system by detecting pathogen 
associated molecular patterns (PAMPs) such as viral RNA. TLR7 and TLR8 are receptors for 
single-stranded RNA and are localised on the endosomal membrane. Ligation of these TLRs 
can activate intracellular pathways resulting in the production of IFNs and subsequently 
several anti-viral IFN stimulated genes (ISGs). Variations in TLR7 and some ISGs have been 
shown to be associated with HCV infection outcome (reviewed in (Rauch, Gaudieri et al. 
2009). One such study has shown the association between variations within TLR 7 and HCV 
infection outcome (Schott, Witt et al. 2008). In this study, variants at position 32 and 2403 of 
TLR7 were associated with viral persistence and IFN- treatment outcome. Other genetic 
variations within the ISGs MxA, OAS-1 and PKR have been associated with HCV infection 
outcome (Knapp, Yee et al. 2003) (Table 2). 
Not surprisingly, polymorphisms in genes encoding cytokines and chemokines have been 
associated with HCV outcome. A recent meta-analysis on IL-10 gene polymorphisms and 
HCV infection outcome found the IL-10 (-1082) GG genotype was more frequent in 
subjects with persistent HCV infection and correlated with higher IL-10 serum levels 
(Zhang, Zhang et al. 2010). IL-12 plays an important role as a pro-inflammatory cytokine 
in T helper 1 lymphocyte differentiation and a study on 123 chronically infected and 72 
spontaneous resolvers showed that viral persistence was associated with homozygosity 
for a 3’UTR variant of IL-12 and correlated with lower production of IL-12 (Houldsworth, 
Metzner et al. 2005).  
3.1.1.2 NK cell KIRs and HLA ligands  
Several groups have investigated the level at which the genetically polymorphic NK 
receptors and ligands influence HCV infection outcome. Two studies have confirmed that 
homozygosity for the NK cell inhibitory receptor KIR2DL3 and its ligand, HLA-C alleles 
belonging to the C1-group (defined by asparagine at residue 80 of the extracellular domain), 
results in a higher probability of resolution of HCV infection (Khakoo, Thio et al. 2004; 
Vidal-Castineira, Lopez-Vazquez et al. 2010).  It has been hypothesised that this combined 
genotype results in relatively weak inhibition of NK cells and therefore protects against 
HCV by rendering NK cells more easily activated than in other subjects.  This would be 
consistent with the interaction between KIR2DL3 and C1-group HLA-C alleles being 
relatively weak compared to the alternative combinations KIR2DL2 + C1 and KIR2D1 + C2 
(Moesta, Norman et al. 2008).  Furthermore, other HLA-C and KIR as well as HLA-B and the 
3D KIR gene interactions are also likely to be involved in HCV resolution as has been shown 
for HIV infection (Gaudieri, DeSantis et al. 2005). 
3.1.1.3 HLA 
Differences in the strength and breadth of CD4+ and CD8+ HCV-specific T cell immune 
responses is an important correlate of HCV infection outcome (Lechner, Wong et al. 2000; 
Lauer, Lucas et al. 2005). Host HLA molecules govern the cellular T lymphocyte response to 
HCV and accordingly HLA class I and class II alleles have been associated with HCV 
outcome. Genetic association studies have shown that HLA class I alleles HLA-B*27, -A*11, -
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Cw*01, -A*03 and -B*57 are associated with viral clearance, while HLA-B*38, -Cw*07, -B*08 
and -A*01 are associated with viral persistence or chronic infection. HLA class II alleles, 
which present antigen to CD4+ T cells, are also shown to be associated with viral clearance 
or persistence. HLA-DRB1*04, -DRB1*11, -DQB1*03 and -DRB1*01 are associated with viral 
clearance, while HLA-DRB4*01 and -DRB1*07 are associated with chronic infection 
(reviewed in (Rauch, Gaudieri et al. 2009; Schmidt, Thimme et al. 2011) (Table 2).  
Studies of HCV single source outbreaks provides the opportunity to examine the influence 
of HLA by removing or reducing confounding effects such as gender and age. One study on 
individuals from an Irish HCV single source outbreak including 227 women (141 chronic 
and 86 cleared) that were exposed to HCV contaminated immunoglobulin showed the 
association of HLA-B*27 with spontaneous resolution (McKiernan, Hagan et al. 2004). This 
study highlights the contribution of the host’s immune CD8+T cell response and HLA genes 
to HCV outcome. However, the relationship between HLA and HCV outcome should be 
considered in the context of viral variation. It is likely that viral immune escape mutations 
present in the incoming virus will affect HCV infection outcome as has been shown using 
single source outbreak cohorts (Merani, Petrovic et al. 2011) (Salloum, Oniangue-Ndza et al. 
2008). Accordingly, viral adaptation to the host’s HLA-restricted immune response will be 
an important correlate of infection outcome (Figure 1). 
3.1.2 GWAS  
The initial association between polymorphisms upstream of IL28B and HCV infection 
outcome were identified using GWAS. GWAS are used to identify single nucleotide 
polymorphisms (SNPs) associated with disease outcome without a priori knowledge. The 
method screens a large number of host variants in hundreds or thousands of case/control 
subjects. The SNPs are pre-selected based on how well they “tag” certain areas or genes due 
to the linkage disequilibrium pattern across the genome, such that not all of the more than 
three million base differences (on average) between two unrelated individuals need be 
sampled. Although tagging SNPs may not necessarily be the causative variation they are 
likely to be near putative causative variations that can be further investigated.  
Rauch et al utilised a GWAS to identify host genetic factors associated with HCV 
spontaneous clearance (Rauch, Kutalik et al. 2010) . The SNP rs8099917 upstream of the gene 
IL28B was the strongest predictor for HCV clearance (OR=2.31, CI=1.74-3.04). Similarly, 
Thomas et al also showed a SNP upstream of IL28B was associated with spontaneous 
resolution of HCV in different ethnic groups (European OR=2.6, CI=1.9-3.8 and African 
OR=3.1, CI=1.7-5.8); in this case the SNP was rs12979860 (Thomas, Thio et al. 2009). 
Individuals homozygous for the C allele at rs12979860 were more likely to clear HCV 
infection than individuals with the CT or TT genotype. The protective effect of the CC 
genotype was seen in subjects belonging to Caucasian as well as African-American ethnicity. 
Although the two studies identified different SNPs, both flanked the IL28B gene and are 
likely to reflect a protective IL28B haplotype. 
IL28B encodes for the type III IFN-3. IFN- stimulates an intracellular cascade that turns on 
IFN-/ like anti-viral responses. In addition, IFN- plays a vital role in inhibiting HCV 
manifestations by interfering with virus replication (Robek, Boyd et al. 2005). Furthermore, 
genetic variations upstream and flanking IL28B may correlate to different expression levels 
and many groups are now trying to understand the role of IFN- in HCV infection. 
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3.2 Host and viral factors influencing treatment response 
The current standard of treatment for HCV is pegIFN-RBV. However, this treatment 
regimen is associated with several severe side-effects and sustained virological responses 
(SVR) is observed in 30-80% subjects. Several factors have been shown to be predictive of 
SVR, which include HCV genotype (GT) and pre-treatment viral load. Subjects infected with 
GT 1 have a low SVR rate of less than 50%, while subjects infected with GTs 2 or 3 have 
higher SVR rates of approximately 80% (Selzner and McGilvray 2008).  
Various approaches such as candidate gene studies and GWAS have identified genes 
associated with different response rates to pegIFN- alone or combination therapy (Table 2). 
The most widely studied genes encode for the IFN genes and ISGs. A study on subjects in 
the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial 
demonstrated associations between variants in IFN-ǂ pathway genes and treatment 
outcome. Specifically, variants in the Interferon α receptor R1 (IFNAR1) (-22T>G), IFNAR2 (-
33T>C), Janus kinase 1 (JAK1) (+112G>T) were associated with SVR. The Tyrosine kinase 2 
(TYK2) -2256 A allele was also associated with SVR (Welzel, Morgan et al. 2009).  Su et al 
examined the association in 12 ISGs in 374 treatment naïve HCV subjects. Three SNPs  in the 
IFN induced 2’-5’ oligoadenylated synthetase -like gene (OASL) (rs3213545 T , rs1169279 A and 
rs2859398 C alleles) were found to be associated with SVR (Su, Yee et al. 2008). The T allele 
in the promoter (–88) of MxA was also associated with SVR (Suzuki, Arase et al. 2004). 
Although these association studies highlight the relevance of IFN and ISG variants in HCV 
treatment, additional gene expression studies have been carried out to directly correlated 
expression levels with treatment outcome. Chen et al identified 18 differentially expressed 
genes in liver biopsy samples obtained before the commencement of IFN-ǂ treatment. Most 
differentially expressed genes in treatment responders and treatment non responders were 
IFN sensitive genes (including OAS2 and 3 and MxA) and two (ISG15/USP18) belonged to 
the IFN regulatory pathway (Chen, Borozan et al. 2005). Up regulation of ISG15/USP18 was 
identified as a predictor of IFN therapy outcome. ISG15, a ubiquitin-like protein, and USP18, 
part of the protease pathway, are thought to be important in host innate defense immunity.  
Four independent groups utilised GWAS to evaluate the association between SNPs in the 
human genome and HCV treatment outcome (Ge, Fellay et al. 2009; Suppiah, Moldovan et 
al. 2009; Tanaka, Nishida et al. 2009; Rauch, Kutalik et al. 2010). The SNP rs8099917 located 
10kb upstream of the IL28B gene (discussed above) was identified in all four studies as 
showing a significant association with HCV treatment outcome. SNP rs12979860 located 3kb 
upstream of IL28B was shown by Ge and colleagues (Ge, Fellay et al. 2009) to also be 
associated with HCV treatment outcome. The four studies included different ethnic groups 
but genotyping and analytical methods were similar, although the type of commercial SNP 
set used by the groups varied and may account for the lack of detection of SNP rs12979860 
in some of the studies (Rauch, Rohrbach et al. 2010). The same SNPs upstream of IL28B were 
associated with HCV treatment and infection outcome. 
The GWAS performed by Ge et al utilised subjects in the IDEAL study; a large randomized 
control trial comparing the effectiveness of different forms of pegIFN-Ge, Fellay et al. 
. The North American study included 1137 subjects from three ethnics groups 
Caucasian, African American and Hispanic. Seven SNPs were reported to be associated with 
treatment outcome with the SNP rs12979860 having the strongest correlation to treatment 
outcome with the CC genotype showing a two-fold greater rate of SVR than genotype TT in 
www.intechopen.com
Genetic Variation of Host Immune Response Genes  
and Their Effect on Hepatitis C Infection and Treatment Outcome 
 
177 
all ethnics groups. The C allele frequency is highest in south East Asian populations and 
accordingly they achieve the highest SVR with combined therapy than subjects from 
European or African background. Furthermore, the frequency of the protective C allele is 
significantly higher in individuals from European ancestry than African American and 
explains half of the difference in response between the two ethnic groups.   
Interferon inducible gamma 10kDa protein (IP-10), which belongs to the chemokine family 
has also been identified as a predictor of treatment response. The low plasma level of IP-10 
was shown to be associated with a decrease in HCV RNA and SVR in early or first phase of 
treatment (Askarieh, Alsiö et al. 2010). In another study by Lagging et al, they correlated 
variants in three SNPs related to IL-28B with pre-treatment plasma levels of IP-10 (Lagging, 
Askarieh et al. 2011). These studies suggest assessment of IP-10 levels and testing of IL-28B 
variants can help predict treatment response in a clinical setting.  
Cytokines profiles have been studied with respect to viral clearance and persistence during 
the current treatment regime. Polymorphisms in IL-12, IL-18, IL-10 cytokines have been 
shown to be associated with HCV treatment outcome (Wan, Kung et al. 2009). The findings 
of most of these studies are inconsistent reflecting the differences in study design and likely 
ethnic differences.  
Similar to host genetic factors, genetic variability within the viral genome is likely to 
influence treatment response. Studies have indicated that amino acid substitutions in the 
core region (70 and 91), which forms the nucleocapsid of HCV, are related to treatment 
outcome. Similarly, amino acid substitutions in the interferon sensitivity determining region 
(ISDR) located in the non-structural 5A region (NS5A) of the viral genome is found to be 
associated with favorable treatment outcome (Maekawa and Enomoto 2009).   
Better understanding of the complex interactions between genes and environmental factors 
may significantly help in predicting the response to current HCV therapy in the future. 
3.3 Host and viral factors influencing disease progression 
Chronic liver disease is a known morbidity of HCV infection with 20% of chronic HCV cases 
developing these complications, of which approximately 5% go on to develop hepatocellular 
carcinoma. Studies have shown demographic as well as epidemiological factors are 
associated with progression to fibrosis. Some subjects progress rapidly to early stage of 
fibrosis, while some do not develop fibrosis. Thus genetic factors predisposing to fibrosis are 
crucial in pathogenesis of hepatic fibrosis.  
Pro-inflammatory and anti-inflammatory genes have been shown to be associated with liver 
disease progression in HCV. The anti-inflammatory cytokine IL-10 is likely to have an 
immuno-modulatory role in fibrosis. Promoter polymorphisms in IL-10, which affect the 
level of IL-10 production, have been shown to be associated with susceptibility to liver 
fibrosis. In a study of Japanese chronic HCV subjects, the IL-10 -824 T allele, -1087 A allele 
and -1087/-824 haplotypes AT and AC were shown to be risk factors for progression of 
hepatic fibrosis (Ishida, Ikebuchi et al. 2011). Another study investigated the combined effect 
of SNPs in IL-10, IL-18 and IFN-Ǆ genes on 77 chronic HCV infected patients. Subjects 
carrying 3-4 high risk genotypes were associated with greater risk of developing liver 
cirrhosis (Bouzgarrou, Hassen et al. 2011).  
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Risk factors identified in these studies would help in understanding the molecular 
mechanisms involved in pathogenesis of chronic liver disease in HCV infected individuals. 
Such studies may also provide new insights for developing drug targets thus reducing the 
burden of HCV worldwide. 
4. HCV diversity and viral adaptation 
As HCV is an obligate intracellular virus with a small RNA genome, it evolves by 
escaping/adapting to the host’s immune response. The mechanisms utilised by HCV to 
establish persistent infection are not fully understood but involve several strategies (Nolan, 
Gaudieri et al. 2006).  
HCV has a high mutation rate due to the lack of proof-reading activity of its RNA 
dependent RNA polymerase. This characteristic along with the high rate of replication of 
HCV results in the circulation of genetically related variants/quasispecies within the 
infected individuals. In addition, HCV is classified into six major GT and more than 50 
different subtypes based on the sequence variability of the virus. GTs 1 and 3 are the most 
prevalent GTs and also account for the majority of HCV infections worldwide (Chayama 
and Hayes 2011).  
The efficacy of HCV-specific T lymphocyte responses is therefore compromised by the 
mutability of the viral genome within HLA Class I and II-restricted epitopes and this 
represents a potent escape strategy of HCV (Timm, Lauer et al. 2004; Thimme, Lohmann et 
al. 2006) as well as other viruses such as HIV (Goulder and Watkins 2004). These mutations 
may exist in the infecting virus or arise in-vivo can affect HLA-peptide binding and therefore 
influence the selection of peptides presented by an individual. These mutations may also 
impair HLA-peptide and T lymphocyte interaction and reduce the efficiency of the T 
lymphocyte-mediated immune response. The relevance of HCV immune escape mutations 
in chronic infection  was first demonstrated in chimpanzees (Weiner, Erickson et al. 1995; 
Erickson, Kimura et al. 2001; Grakoui, Shoukry et al. 2003) and subsequently in humans 
(Cox, Mosbruger et al. 2005; Tester, Smyk-Pearson et al. 2005) (reviewed in (Bowen and 
Walker 2005). Evidence for T lymphocyte escape and reversion has also been recently 
demonstrated in acute infection (Timm, Lauer et al. 2004) and 18-22 years after a common-
source outbreak (Ray, Fanning et al. 2005). Flanking epitope escape mutations have also 
been described and alter proteasomal epitope processing and subsequent peptide 
presentation (Seifert, Liermann et al. 2004). Overall, this emphasizes the complexity of 
multiple effective mechanisms of T lymphocyte immune escape in HCV.  
Studies utilizing population-based genetic approaches, which examine the association 
between specific viral polymorphisms and the HLA types of individuals within a host 
population, have demonstrated viral escape (adaptation) to HLA-restricted immune 
pressure evident at the population level for both HIV and HCV (Gaudieri, Rauch et al. 2006; 
Timm, Li et al. 2007) . The approach is based on the premise that the host’s HLA molecules 
regulate immune responses by presenting specific viral epitopes to T lymphocytes and viral 
polymorphisms within or flanking these epitopes that compromise the efficacy of these T 
lymphocyte responses (i.e. allow viral escape) would be identified as HLA-specific HCV 
polymorphisms (viral adaptations). Accordingly, HCV can escape host immune responses 
via mutations that confer a selective advantage resulting in the fixation (or dominance) of 
specific strains within the host and to some extent drive HCV evolution. 
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Given the extent of sequence diversity between the GTs (Figure 2), it would be anticipated 
that the sequence context of epitopes restricted for specific HLA molecules would  
be altered and potentially disrupted for other GTs. The initial population-based genetic 
study on HCV GT 1 (Gaudieri, Rauch et al. 2006)  was extended to examine  
HCV adaptation to HLA-restricted immune responses in GT 3 (Rauch, James et al. 2009). 
The study reported that the immune escape profiles differ between the two main 
circulating GTs 1 and 3 reflecting the extensive variation between the GTs and the 
observation that individuals can clear one GT but can be re-infected with other GTs with 
limited protection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. HCV diversity in the (a) NS3 and (b) NS5B regions for Caucasian chronic HCV 
populations. 
5. Summary 
Host and viral genetic determinants within genes related to the host immune response are 
important in determining infection outcome, including HCV outcome. Studies accounting 
for variability in both host and pathogen are likely to provide a more complete 
understanding of the complex host/pathogen interaction and its variable outcomes. 
Specifically, an understanding of how viral adaptation to host HLA-restricted immune 
responses (and perhaps to NK cells given recent evidence of “footprints” in HIV genome 
due to KIR genotypes; (Alter, Heckerman et al. 2011)) affects infection outcome will provide 
an insight into vaccine design. 
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Given our current knowledge, the HCV virus would be particularly amenable to a T 
lymphocyte vaccine strategy given that immunity in those that control the virus consists of 
broad T lymphocyte responses and viral structural constraints that prevent escape from all 
mounted T lymphocyte responses. Identifying the viral T lymphocyte targets of a successful 
host immune response is crucial to vaccine design and should consider the genetic diversity 
of the virus as well as the HLA genetic system of the host population for which the vaccine 
is designed.   
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